(Q39122521)

9 September 2017

title

Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model (English)

1 reference

9 September 2017

0 references

1 reference

1 reference

1 reference

5

Jürgen Borlak

1 reference

9 September 2017

Nour Karra

1

1 reference

9 September 2017

Taher Nassar

2

1 reference

9 September 2017

Alina Nemirovski Ripin

3

1 reference

9 September 2017

Ouri Schwob

4

1 reference

9 September 2017

Simon Benita

6

1 reference

9 September 2017

publication date

21 July 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

9

1 reference

9 September 2017

issue

24

1 reference

9 September 2017

page(s)

4221-4236

1 reference

The ligand nanoparticle conjugation approach for targeted cancer therapy

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Noncovalent functionalization of carbon nanovectors with an antibody enables targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Biodegradable nanoparticles for direct or two-step tumor immunotargeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Immunogenicity of immunoliposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Characterization and cancer cell specific binding properties of anti-EGFR antibody conjugated quantum dots

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Functionalization of iron oxide nanoparticles with a versatile epoxy amine linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Interfacial activity assisted surface functionalization: a novel approach to incorporate maleimide functional groups and cRGD peptide on polymeric nanoparticles for targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Synthesis of pegylated immunonanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

The effect of hydrophilic chain length and iRGD on drug delivery from poly(ε-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Quantum dot applications to neuroscience: new tools for probing neurons and glia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

A quantitative evaluation of the molecular binding affinity between a monoclonal antibody conjugated to a nanoparticle and an antigen by surface plasmon resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Cetuximab in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Nanoparticles as delivery carriers for anticancer prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Targeted drug delivery to tumors: myths, reality and possibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Vitamin E TPGS as a molecular biomaterial for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Impact of nanotechnology on drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Analysis on the current status of targeted drug delivery to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Receptor-targeted nanoparticles for in vivo imaging of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Method for analysis of nanoparticle hemolytic properties in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FSMLL.201301417

21 January 2018

Identifiers

DOI

10.1002/SMLL.201301417

1 reference

9 September 2017

1 reference